Go to the list of all blogs
Joma Foster's Avatar
published in Blogs
Oct 22, 2026
TickeronGET DAILY SIGNALS
CVS Health (CVS) vs UnitedHealth Group (UNH): Turnaround Momentum Against Diversified Recovery

CVS Health (CVS) vs UnitedHealth Group (UNH): Turnaround Momentum Against Diversified Recovery

Key Takeaways

  • CVS is executing a turnaround, having beaten earnings expectations for five consecutive quarters and raised its 2026 profit guidance after improving medical-cost controls.
  • UNH is the larger, more diversified operator and has raised its full-year earnings outlook multiple times in 2026 as its insurance margins recover.
  • Both companies face elevated medical costs and tight Medicare Advantage (MA) margins, a shared headwind across the managed-care sector.
  • CVS carries greater exposure to retail pharmacy and pharmacy benefit manager (PBM) regulation, while UNH is diversified through its Optum services division.
  • Each stock has posted strong year-to-date gains, but their paths reflect different trade-offs between growth and profitability.

Introduction

CVS Health and UnitedHealth Group rank among the largest players in U.S. healthcare, yet they operate with distinctly different models. CVS combines a national retail pharmacy network, the Aetna insurance arm, and the Caremark pharmacy benefit manager. UNH pairs the nation’s largest health insurer with Optum, its expanding healthcare-services business. This comparison matters for investors looking to weigh an integrated retailer-insurer’s recovery against a diversified managed-care leader that is regaining margin ground. Examining their performance, positioning, and risks can clarify which approach fits the current environment best.

CVS Overview and Recent Performance

CVS Health breaks down into three segments: Health Care Benefits (Aetna), Health Services (Caremark PBM), and Pharmacy & Consumer Wellness. After a tough 2024 that included an earnings miss and a CEO change, the company has regained traction. In the latest quarter, adjusted EPS climbed roughly 14% year over year to $2.57, topping estimates, while revenue rose about 6% to near $100 billion. Management lifted full-year 2026 adjusted EPS guidance to a range of $7.30 to $7.50. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Aetna drove much of the improvement, with the medical benefit ratio falling to 84.6% from 87.3% a year earlier, reflecting better cost discipline. Recent developments include an FTC settlement on Caremark’s payment model and a move toward biosimilars. These factors have helped shares approach a 52-week high, though Medicare Advantage margins and pharmacy reimbursement pressures remain key risks.

UNH Overview and Recent Performance

UnitedHealth Group operates UnitedHealthcare, the largest U.S. health insurer, together with Optum, which covers pharmacy services, care delivery, and data and technology. Following a difficult 2025 shaped by higher medical costs and regulatory attention, the company has posted a clearer earnings rebound. Adjusted EPS jumped about 61% year over year to $4.69 in the most recent quarter, beating expectations, while revenue eased slightly to roughly $113 billion. Management raised its 2026 adjusted EPS outlook to at least $20.50. The medical care ratio improved to 88.4% from 89.9% a year earlier. From what I see, the firm has deliberately allowed membership to decline to about 48.3 million as it favors profitable growth, especially in Medicare Advantage. Optum’s services turnaround has added support. A recent note that Berkshire Hathaway exited its stake, along with ongoing commercial-cost pressures, has kept sentiment measured.

Head-to-Head Comparison

On business model, CVS is an integrated healthcare conglomerate whose results depend on Aetna’s turnaround plus managing PBM regulatory changes and a lower-margin retail pharmacy operation. UNH is a managed-care leader diversified into Optum, which provides more balanced revenue streams but also broad exposure to insurance utilization trends. On scale, UNH is larger, with full-year revenue expected near $450 billion compared with CVS guidance of at least $405 billion. Both stocks have outperformed recently, though through different drivers. CVS gains stem from insurance-margin recovery and guidance increases after earlier underperformance, while UNH reflects a return to earnings growth even as membership contracts. On risk, CVS faces greater pharmacy reimbursement and PBM regulatory exposure, whereas UNH contends with commercial medical-cost trends and legal scrutiny. Analyst estimate revisions have trended higher for both, though UNH trades at a richer valuation multiple relative to its peers.

My Experience with Tickeron AI Tools

I have found Tickeron’s Trending AI Robots page useful when comparing names like these. It highlights automated strategies that fit current market conditions, each with its own style, timeframe, and documented performance metrics. Reviewing the selection helps put the relative momentum of CVS and UNH into perspective without replacing deeper fundamental work.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: UNH, CVS

UNH's RSI Oscillator is staying in oversold zone for 2 days

It is expected that a price bounce should occur soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +1.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where UNH advanced for three days, in 187 of 331 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.

UNH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on UNH as a result. In 56 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 67%.

The Moving Average Convergence Divergence Histogram (MACD) for UNH turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 27 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 59%.

UNH moved below its 50-day moving average on November 17, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for UNH crossed bearishly below the 50-day moving average on November 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 67%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where UNH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 52%.

The Aroon Indicator for UNH entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. UNH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.594) is normal, around the industry mean (3.520). P/E Ratio (25.266) is within average values for comparable stocks, (126.353). Projected Growth (PEG Ratio) (1.025) is also within normal values, averaging (0.786). UNH has a moderately high Dividend Yield (0.024) as compared to the industry average of (0.009). P/S Ratio (0.757) is also within normal values, averaging (0.569).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UNH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

Notable companies

The most notable companies in this group are Unitedhealth Group (NYSE:UNH), CVS HEALTH Corp (NYSE:CVS), Elevance Health (NYSE:ELV), Cigna Group (The) (NYSE:CI), Humana (NYSE:HUM), Centene Corp (NYSE:CNC).

Industry description

Managed healthcare industry focuses on providing health/medical and disability insurance plans, generally intended to reduce the cost of for-profit health care. The insurance products might be provided through employer-paid (fully or partly) insurance and benefit programs, or through Medicare/Medicaid. Some of the largest providers of managed health care include Aetna, Humana Inc., and Cigna, and UnitedHealthcare.

Market Cap

The average market capitalization across the Managed Health Care Industry is 67.69B. The market cap for tickers in the group ranges from 335.99K to 353.79B. UNH holds the highest valuation in this group at 353.79B. The lowest valued company is IHGP at 335.99K.

High and low price notable news

The average weekly price growth across all stocks in the Managed Health Care Industry was -12%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was 1%. PGNY experienced the highest price growth at -1%, while CLOV experienced the biggest fall at -25%.

Volume

The average weekly volume growth across all stocks in the Managed Health Care Industry was 80%. For the same stocks of the Industry, the average monthly volume growth was 91% and the average quarterly volume growth was 67%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 44
Price Growth Rating: 54
SMR Rating: 72
Profit Risk Rating: 91
Seasonality Score: -6 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of hospital and medical service plans

Industry ManagedHealthCare

Industry
Managed Health Care
Address
1 Health Drive
Phone
+1 800 328-5979
Employees
390000
Web
https://www.unitedhealthgroup.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.